These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from July 27 through Aug. 2, 2023. Source: VerityData
Original Filings
Apogee Therapeutics
(APGE)
Venrock reported a fresh position in the biotech company of 3,887,478 shares. That amount includes 1,750,000 Apogee Therapeutics shares that Venrock purchased through the pharmaceutical’s July 13 initial public offering that priced shares at $17 each. Venrock holds a 9.99% interest in Apogee.
It also holds additional nonvoting Apogee Therapeutics shares that may be converted into common stock on a one-for-one basis, provided Venrock owns no more than 10% of the pharmaceutical’s outstanding stock. They are excluded from the above ownership figures.
Turnstone Biologics
(TSBX)
Versant Venture Capital disclosed a new position in the clinical-stage pharmaceutical company of 2,899,216 shares. The figure includes 225,000 shares that Versant bought through Turnstone Biologics’ IPO at a price of $12 each.
After the IPO closed on July 25, Versant Venture held 12.5% of Turnstone Biologics’ tradable stock. Turnstone Biologics is developing new medicines to treat and cure solid tumors. Its president and CEO, Sammy Farah, previously served at Versant Venture, where he specialized in biotechnology investing and forming new companies.
Decreases in Holdings
Vera Therapeutics
(VERA)
Carlyle Group
(CG) reduced its position in the pharmaceutical company to 1,872,764 shares. Carlyle sold 544,073 Vera Therapeutics shares from July 11 through July 31 at prices ranging from $16.97 to $18.84 each. Following those sales, Carlyle holds a 4.2% interest in Vera Therapeutics, below the 5% threshold that would require disclosure of any further Vera Therapeutics stock sales.
St. Joe
(JOE)
Fairholme Capital Management lowered its holding in the real estate development company to 23,349,948 shares. From June 2 through Aug. 1, Fairholme sold 787,200 St. Joe shares at prices ranging from $46.01 to $64.95 each. Fairholme Capital remains St. Joe’s largest shareholder with a 40% stake. St. Joe’s stock has gained approximately 57% year to date.
Oil-Dri Corp. of America
(ODC)
Gamco Investors
(GAMI) trimmed its stake in the specialty sorbent products maker to 530,406 shares. Gamco sold 52,900 Oil-Dri shares from June 5 through July 28 at prices ranging from $38.59 to $63.67 apiece. After the sales, Gamco holds a 10.4% interest in Oil-Dri. The stock has been on a tear, surging about 90% so far this year.
Oil-Dri’s specialty sorbent products are designed for a variety of markets, including pet care; animal health and nutrition; bleaching clay and fluids purification; agricultural ingredients; sports field; industrial; and automotive. The company recently announced 10% to 15% price increases on its industrial and automotive clay absorbents, effective on Sept. 1, citing rising costs of mining, maintenance, and labor.
Email: [email protected]
Read the full article here
